One hour of training. 96% imageability. Zero pupil dilation. That's diabetic eye screening with AEYE-DS in a busy, real-world clinic, from a new study just published in the British Journal of Ophthalmology. Read more here: aeyehealth.com/news

Happy National Nurses Month! 💙 To the front-line nurses who show up every day with compassion, resilience, and unwavering dedication - thank you! From chronic disease management and early detection to care coordination, practice operations, and patient support, nurses are at the center of healthcare. At AEYE Health, we’re proud to support care teams with a solution that seamlessly integrates diabetic retinopathy screening into everyday visits, making it easier to deliver preventive care, close gaps, and protect patient’s vision. Your impact extends across the entire patient journey, and goes far beyond what can be measured. Thank you for your commitment to elevating patient care every single day! #NationalNursesMonth #PrimaryCare #DiabeticRetinopathy #PreventiveHealth

𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗶𝘀 𝗴𝗿𝗲𝗮𝘁. 𝗔𝗰𝗰𝗲𝘀𝘀 𝗶𝘀 𝗯𝗲𝘁𝘁𝗲𝗿. This Healthy Vision Month, we’re looking past patient-facing campaigns to a harder truth: The bottleneck in diabetic eye care isn't a lack of awareness- it's structural friction Despite clear guidelines, 60% of patients still miss their annual screenings. Traditional referral loops and high "ungradable" rates in teleretinal programs create a persistent blind spot in population health. The shift toward Point-of-Care: As highlighted in the 2026 ADA Standards of Care, moving screening into the primary care setting is the only way to optimize the "last mile" of delivery. This is where AI is becoming a core infrastructure layer in diabetic eye care, enabling scalable population health through immediate screening in primary care and real-time detection of referable disease. It reduces reliance on specialists and replaces referral-based bottlenecks with point-of-care delivery. That’s why more health systems are moving diabetic eye screening into primary care. With AEYE-DS, our autonomous AI diabetic retinopathy solution, providers can evaluate patients during routine visits and receive immediate results. As the only FDA-cleared solution compatible with a portable camera, AEYE-DS enables true point-of-care deployment with just one image per eye in under a minute, making diabetic eye screening a seamless part of routine workflows. As healthcare continues shifting toward value-based care, the question isn’t whether this matters. It’s whether our workflows make it easy enough to happen consistently. Healthy Vision Month highlights the importance of aligning infrastructure with real-world patient needs and the role of AI-enabled solutions in making that alignment possible. 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝘁𝗼 𝗲𝘅𝗽𝗹𝗼𝗿𝗲 𝗵𝗼𝘄 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄 𝗮𝗻𝗱 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 𝗰𝗮𝗻 𝗶𝗺𝗽𝗿𝗼𝘃𝗲 𝗱𝗶𝗮𝗯𝗲𝘁𝗶𝗰 𝗲𝘆𝗲 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗮𝘁 𝘀𝗰𝗮𝗹𝗲: lnkd.in/drY7NQmk #HealthyVisionMonth #PopulationHealth #DiabetesCare #DiabeticRetinopathy #PrimaryCare #ValueBasedCare

𝗦𝘂𝗰𝗰𝗲𝘀𝘀 𝗶𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝘀𝘁𝗮𝗿𝘁𝘀 𝘄𝗶𝘁𝗵 𝗮 𝘀𝗵𝗮𝗿𝗲𝗱 𝘃𝗶𝘀𝗶𝗼𝗻. 👁️ Last week, our sales team gathered at our New York City office for an intensive 2-day planning session. We weren’t just talking numbers; we were aligning on our 2026 roadmap to better support providers in closing the gap in diabetic retinopathy screening. Our mission remains clear: to eliminate preventable vision loss by removing barriers to diabetic eye care and ensuring AEYE-DS is seamlessly integrated into every patient visit. Beyond the strategy sessions, we also stepped into the kitchen for a team cooking workshop🥘. It was a great way to recharge and a reminder that while our AI is autonomous, our success is built on the people. #TeamWork #SalesTeam #NYC #GoToMarket

𝗔𝗗𝗔 𝟮𝟬𝟮𝟲 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝘀 𝗼𝗳 𝗖𝗮𝗿𝗲: 𝗧𝗵𝗲 𝗢𝗳𝗳𝗶𝗰𝗶𝗮𝗹 𝗦𝗵𝗶𝗳𝘁 𝘁𝗼 𝗔𝘂𝘁𝗼𝗻𝗼𝗺𝗼𝘂𝘀 𝗔𝗜 𝗶𝗻 𝗣𝗿𝗶𝗺𝗮𝗿𝘆 𝗖𝗮𝗿𝗲 The release of the American Diabetes Association's (ADA) 2026 Standards of Care in Diabetes represents more than a clinical update; it is a structural transformation in the delivery of diabetic eye care. For years, the referral-based models for diabetic retinopathy screening have struggled to close the care gap: the long wait time and fragmented workflows mean the vast majority of patients miss their essential annual screenings. AEYE-DS closes the diabetic eye care gap by bringing screening directly to the point of care. With the ADA guidelines now recognizing autonomous AI as a leading standard for primary care, AEYE-DS transforms vision preservation into a seamless, accessible part of every routine visit. 𝗔𝗘𝗬𝗘-𝗗𝗦: 𝗥𝗲𝗰𝗼𝗴𝗻𝗶𝘇𝗲𝗱 𝗮𝘀 𝘁𝗵𝗲 𝗡𝗲𝘄 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱 Recognized within the highest tier of clinical validation, AEYE-DS fulfills the ADA’s goal of bringing vision-saving screening to where it’s needed most, in primary care: ⬥𝗣𝗼𝗿𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗮𝗻𝗱 𝗨𝘀𝗮𝗯𝗶𝗹𝗶𝘁𝘆: As the only FDA-cleared AI for portable cameras and only AI that requires just 1 image per-eye for the analysis and no dilation, AEYE-DS delivers the fast, accessible, point-of-care diagnosis the 2026 ADA Standards now demand. ⬥𝗜𝗺𝗺𝗲𝗱𝗶𝗮𝘁𝗲 𝗥𝗲𝘀𝘂𝗹𝘁𝘀: AEYE-DS delivers an autonomous diagnosis at the point of care, eliminating the need for physician interpretation, and ensuring patients are successfully screened and notified of their result during the same visit. ⬥>𝟵𝟵% 𝗜𝗺𝗮𝗴𝗲𝗮𝗯𝗶𝗹𝗶𝘁𝘆: A superior "success rate" that ensures virtually every patient can be screened successfully before they leave the clinic. ⬥𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆: Autonomous AI manages routine diagnostics, allowing specialists to focus on treatment while seamless EHR integration automates everything - documentation, billing, care cap closure coding and even referral triggers for the patients found positive for referable DR. ⬥𝗩𝗲𝗿𝗶𝗳𝗶𝗲𝗱 𝗥𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁: Fully reimbursable under CPT 92229, finally enabling financial viability of AI-based screening. By adopting AEYE-DS, providers can move beyond the “referral black hole” and deliver the new gold standard in vision preservation. 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝘁𝗼 𝘀𝗲𝗲 𝗵𝗼𝘄 𝗔𝗜 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝗶𝘀 𝗿𝗲𝗱𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝗱𝗶𝗮𝗯𝗲𝘁𝗶𝗰 𝗲𝘆𝗲 𝗰𝗮𝗿𝗲: aeyehealth.com/post/defining…

𝗧𝗵𝗿𝗲𝗲 𝗰𝗶𝘁𝗶𝗲𝘀. 𝗢𝗻𝗲 𝗴𝗼𝗮𝗹: 𝗖𝗹𝗼𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝗱𝗶𝗮𝗯𝗲𝘁𝗶𝗰 𝗲𝘆𝗲 𝗲𝘅𝗮𝗺 𝗰𝗮𝗿𝗲 𝗴𝗮𝗽. This April we had the privilege of joining the C. Frank Webber Lectureship and Interim Session hosted by the @TXFamilyDocs - the Texas Academy of Family Physicians, Ignite, the Florida Academy of Family Physicians (FAFP) flagship spring forum, and the American Medical Group Association (AMGA) 2026 Annual Conference. Each event had its own focus, but one question united every leader we met: How do we close the diabetic eye exam care gap? There is a growing realization that the current referral-heavy model to eye specialists does not achieve high enough adherence and creates a real barrier to care, as the vast majority don’t follow through. This realization has led to a shared commitment to ensuring no patient loses their sight due to a preventable gap. It was especially exciting to see strong interest and engagement around AEYE-DS, our FDA-cleared solution that is now the fastest-growing solution in America. A fully autonomous AI diabetic retinopathy screening solution that can be performed anywhere, in under a minute, using just one image per eye to deliver on-the-spot results at the point of care. Enabling immediate diagnosis helps enable more efficient, point-of-care workflows and helps bring advanced care directly into everyday clinical practice. We’re grateful for the opportunity to connect, share, and learn from so many forward-thinking clinicians and healthcare leaders who are committed to improving patient outcomes.

Primary care is at a breaking point. Between the mounting pressure to deliver earlier interventions and the struggle to manage expanding patient panels, "closing care gaps" often feels like a moving target, especially for diabetic retinopathy. Traditionally, screening requires external referrals and separate specialist visits, resulting in low patient follow-through. For health systems, this friction creates persistent care gaps, lower HEDIS scores, and leads to the most frustrating outcome of all: preventable vision loss. 𝗧𝗵𝗮𝘁’𝘀 𝘄𝗵𝘆 𝘄𝗲’𝗿𝗲 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗔𝗠𝗚𝗔 𝟮𝟬𝟮𝟲 𝗔𝗻𝗻𝘂𝗮𝗹 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲. AMGA brings together leaders from integrated health systems and medical groups who are actively shaping the future of value-based care, population health, clinical transformation, and multispecialty integration. We are joining this conversation to help health systems move from "managing" gaps to eliminating them through autonomous AI. If you plan to attend, we’d love to connect and demonstrate how AEYE-DS is revolutionizing the standard of care. Our FDA-cleared, fully autonomous AI enables you to close care gaps instantly by delivering a 1-minute diabetic retinopathy diagnosis on the spot - all from a single image per eye. By integrating directly into your EHR, AEYE-DS eliminates administrative friction, maximizes HEDIS scores, and allows you to capture CPT 92229 revenue right at the point of care. Let’s discuss how we can turn a complex referral process into a seamless, one-minute clinical victory for your providers and patients Click the link to book a meeting at the event: aeyehealth.com/lp 📍 Las Vegas, NV | April 15–18, 2026

You’re doing the right thing by referring patients for diabetic eye exams - but too many never make it to that appointment. If you’re attending 𝗜𝗴𝗻𝗶𝘁𝗲, the 𝗙𝗹𝗼𝗿𝗶𝗱𝗮 𝗔𝗰𝗮𝗱𝗲𝗺𝘆 𝗼𝗳 𝗙𝗮𝗺𝗶𝗹𝘆 𝗣𝗵𝘆𝘀𝗶𝗰𝗶𝗮𝗻𝘀 (𝗙𝗔𝗙𝗣) flagship spring forum, there’s a better way to ensure your patients actually get screened! AEYE-DS brings AI diabetic eye exams directly into your visit, delivering a complete, fully autonomous diagnostic result within seconds - before the patient walks out the door. Close the diabetic eye care gap with no physician interpretation, just immediate diagnosis at the point of care. As the only FDA-cleared autonomous AI designed for use with a portable camera - and the only AI that requires just one image per eye - it fits seamlessly into real-world primary care workflows. If you’re attending Ignite, we’d love to connect and explore how AEYE-DS can bring point-of-care diabetic screening directly into your practice. Visit our booth or schedule a time to meet with our team: lnkd.in/drRMAGnZ See you there! 📍 Orlando, FL | April 17-19, 2026

𝗗𝗶𝗮𝗯𝗲𝘁𝗶𝗰 𝗿𝗲𝘁𝗶𝗻𝗼𝗽𝗮𝘁𝗵𝘆 𝗿𝗲𝗺𝗮𝗶𝗻𝘀 𝘁𝗵𝗲 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗰𝗮𝘂𝘀𝗲 𝗼𝗳 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗮𝗯𝗹𝗲 𝘃𝗶𝘀𝗶𝗼𝗻 𝗹𝗼𝘀𝘀 - 𝘆𝗲𝘁 𝗺𝗶𝗹𝗹𝗶𝗼𝗻𝘀 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘀𝘁𝗶𝗹𝗹 𝗺𝗶𝘀𝘀 𝘁𝗵𝗲𝗶𝗿 𝗮𝗻𝗻𝘂𝗮𝗹 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴. Not due to lack of awareness, but due to workflow. The challenge is not clinical knowledge - it is operational execution. Too many steps. Too many handoffs. Too many missed opportunities. Traditional screening depends on external referrals, additional appointments, and disconnected coordination between primary care and eye care. The result is a “specialist bottleneck” that delays diagnosis and leaves the care gap wide open. By embedding AI screening directly into the patient’s charts, screening becomes part of routine clinical workflow rather than a separate process. AEYE-DS transforms the process by embedding FDA-cleared autonomous AI technology directly into the patient’s chart. Screening becomes part of the routine visit, not a separate hurdle. When AEYE-DS integrates into Epic and other major EHRs, a complex referral process becomes a seamless 1-minute exam. This rapid screening requires just one image per eye and produces instant diagnostic results at the point of care. Every step is automated, from documentation in the patient chart, triggering instant referrals when required, and CPT 92229 billing - enabling care gap closure and HEDIS measure improvement. 𝗥𝗲𝗮𝗱 𝗵𝗼𝘄 𝘁𝗼 𝗺𝗼𝘃𝗲 𝗳𝗿𝗼𝗺 𝗯𝗼𝘁𝘁𝗹𝗲𝗻𝗲𝗰𝗸 𝘁𝗼 𝗯𝗲𝗻𝗰𝗵𝗺𝗮𝗿𝗸: lnkd.in/dfiuUpuA

Your diabetic patients are leaving your office without a retinopathy screen. Most won't complete that external referral. If you’re attending the 𝗖. 𝗙𝗿𝗮𝗻𝗸 𝗪𝗲𝗯𝗯𝗲𝗿 𝗟𝗲𝗰𝘁𝘂𝗿𝗲𝘀𝗵𝗶𝗽 𝗮𝗻𝗱 𝗜𝗻𝘁𝗲𝗿𝗶𝗺 𝗦𝗲𝘀𝘀𝗶𝗼𝗻 𝗵𝗼𝘀𝘁𝗲𝗱 𝗯𝘆 𝘁𝗵𝗲 @TXFamilyDocs - 𝗧𝗵𝗲 𝗧𝗲𝘅𝗮𝘀 𝗔𝗰𝗮𝗱𝗲𝗺𝘆 𝗼𝗳 𝗙𝗮𝗺𝗶𝗹𝘆 𝗣𝗵𝘆𝘀𝗶𝗰𝗶𝗮𝗻𝘀, we have a solution to close that gap right in your office. AEYE-DS integrates directly into the primary care visit, completing the exam in just 1-minute, before the patient leaves – eliminating the risk of yet another missed referral. As the only FDA-cleared autonomous AI solution for a portable camera, and the only AI that requires just one image per eye for analysis, it delivers instant diagnostic results at the point of care! Attending the TAFP meeting? Let's chat about integrating AI into your practice. Book your meeting with us here: lnkd.in/djCUTjDy See you there 📍Round Rock, TX | April 10–11, 2026

🚨 𝗧𝗼𝗱𝗮𝘆 𝗶𝘀 𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗔𝗹𝗲𝗿𝘁 𝗗𝗮𝘆 The annual wake-up call from the American Diabetes Association (ADA), serves as a reminder about the growing impact of diabetes - and the importance of early detection and proactive care. The statistics are a call to action: ♦ 𝟭𝟭𝟱𝗠+ people are living with prediabetes and are at high risk of developing diabetes. ♦ 𝟭.𝟱𝗠 people are diagnosed with diabetes every year. ♦ 𝟭 𝗶𝗻 𝟰 adults with diabetes doesn’t know they have it. The ADA encourages everyone to take their quick, 1-minute Diabetes Risk Test , because understanding your risk is the first step toward prevention. In that same spirit, we believe screening for Diabetes complications like diabetic retinopathy, the leading cause of preventable vision loss in the US should be just as practical. At AEYE Health, we know that early detection through point-of-care screening is critical to protecting patients’ vision before complications occur. That’s why we developed AEYE-DS, a 1-minute AI screening designed to make protecting a patient's sight as instant as the risk test itself. That’s why we developed AEYE-DS, a 1-minute AI screening designed to protect a patient's sight as instant as the risk test itself. Take 1 minute for your health today, and please encourage your loved ones to do the same. 𝗧𝗮𝗸𝗲 𝘁𝗵𝗲 𝗔𝗗𝗔 𝗥𝗶𝘀𝗸 𝗧𝗲𝘀𝘁: lnkd.in/dUNXrWAh 𝗦𝗲𝗲 𝗵𝗼𝘄 𝗔𝗜 𝗶𝘀 𝘀𝗮𝘃𝗶𝗻𝗴 𝘃𝗶𝘀𝗶𝗼𝗻: lnkd.in/g8smgcVz hashtag#DiabetesAlertDay hashtag#DiabetesAwareness hashtag#PreventiveCare hashtag#AmericanDiabetesAssociation hashtag#ADA

𝗟𝗮𝘀𝘁 𝘄𝗲𝗲𝗸 𝘄𝗲 𝗰𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗲𝗱 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗪𝗼𝗺𝗲𝗻’𝘀 𝗗𝗮𝘆, 𝗮𝗻 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝘆 𝘁𝗼 𝗰𝗲𝗹𝗲𝗯𝗿𝗮𝘁𝗲 𝘄𝗼𝗺𝗲𝗻 - 𝗮𝗻𝗱 𝘁𝗼 𝗿𝗮𝗶𝘀𝗲 𝗮𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗮𝗯𝗼𝘂𝘁 𝘄𝗼𝗺𝗲𝗻’𝘀 𝗵𝗲𝗮𝗹𝘁𝗵. Did you know that nearly 20 million women in the U.S. are living with diabetes? Diabetes can lead to many serious health complications, including diabetic retinopathy, one of the leading causes of preventable vision loss. Early detection is key - that’s why we developed AEYE-DS, the only FDA-cleared autonomous AI solution for point-of-care diabetic retinopathy screening that works with a portable camera and performs a 1-minute eye exam using just one image per eye, helping ensure patients receive timely follow-up care. Supporting women’s health means protecting their vision - because awareness and early detection save sight. 💡 Contact us to learn more - google.com/url?q=https://www…

𝗧𝗵𝗲 𝗘𝗻𝗱 𝗼𝗳 𝘁𝗵𝗲 𝗕𝗹𝗼𝗼𝗱 𝗣𝗿𝗲𝘀𝘀𝘂𝗿𝗲 𝗖𝘂𝗳𝗳? 𝗛𝗼𝘄 𝗔𝗘𝗬𝗘’𝘀 𝗔𝗜 𝗳𝗼𝗿 𝗿𝗲𝘁𝗶𝗻𝗮𝗹 𝗶𝗺𝗮𝗴𝗲𝘀 𝗥𝗲𝗱𝗲𝗳𝗶𝗻𝗲𝘀 𝗖𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗠𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 We are proud to share that our latest research has been published in BMJ Innovations. The study demonstrates that our AI technology can estimate blood pressure from a single non-mydriatic fundus image (a simple retinal scan) with accuracy comparable, and even slightly superior to conventional arm cuff measurements, featuring greater consistency and stability. This was done with a large validation dataset comparing the AI’s analysis to multiple cuff measurements. This publication marks a major milestone in demonstrating our technology’s potential to enable a non-invasive, rapid 1-minute cardiovascular assessment without a cuff. 𝗞𝗲𝘆 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀: 𝗡𝗼𝗻-𝗰𝗼𝗻𝘁𝗮𝗰𝘁 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 - A rapid,1-minute cardiovascular assessment without a cuff. 𝗘𝗮𝗿𝗹𝘆 𝗜𝗻𝘁𝗲𝗿𝘃𝗲𝗻𝘁𝗶𝗼𝗻 - Assessing blood pressure and detecting hypertension risk before significant systemic damage occurs. 𝗕𝗲𝘆𝗼𝗻𝗱 𝗘𝘆𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 - Expanding the role of retinal imaging for systemic health assessments. This study also highlights a key research capability of 𝗔𝗘𝗬𝗘-𝗫 - our comprehensive AI diagnostic screening solution, designed to detect a broad range of diseases, currently supporting a wide range of medical indications, and further validating the potential of a routine eye exam to provide meaningful insight into a patient’s both short and long-term cardiovascular health. **AEYE-X, unlike AEYE-DS, is currently not offered for diagnostic purposes in the U.S. Read the full press release: lnkd.in/dRwU9jpK